Epilepsy and IgA deficiency--the effect of sodium valproate. 1977

P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster

IgA deficiency (less than 80 IU/ml serum) occurred in 29% of 41 epileptic patients on anticonvulsant therapy. Sodium valproate users had significantly lower mean IgA levels (102 IU/ml) than non-users (151 IU/ml) and had a significantly higher incidence of IgA deficiency (50%) than non-users (16%). The occurrence of IgA deficiency did not appear to be related to age, sex, number of drugs used or to serum anticonvulsant levels.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000361 Agammaglobulinemia An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood. Hypogammaglobulinemia,Agammaglobulinemias,Hypogammaglobulinemias

Related Publications

P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
February 1984, The Journal of pediatrics,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
October 1977, Lancet (London, England),
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
December 1975, Drug and therapeutics bulletin,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
March 1986, The Practitioner,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
August 1978, Epilepsia,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
June 1974, British medical journal,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
January 1986, Brain & development,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
September 1976, Acta neurologica Scandinavica,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
December 1975, Developmental medicine and child neurology,
P H Joubert, and A K Aucamp, and G M Potgieter, and F Verster
January 1976, Transactions of the American Neurological Association,
Copied contents to your clipboard!